Novo Nordisk launches Wegovy weight-loss pill in US, triggering price war

Novo Nordisk has launched Wegovy, the first GLP-1 weight-loss pill in the US, priced lower than injectable versions, sparking a price war. Available for $5 a day or $149 a month, the pill offers a needle-free alternative to injections, potentially appealing to over 100 million Americans with obesity. The launch has caused Novo Nordisk's share price to rise by over 4%, though it remains down 44% over the past year due to competition from Eli Lilly's jabs. The pill is now available at over 70,000 US pharmacies and telehealth providers, with higher doses to be available later.